Table 4.
Comparison of slope values for concentration-effect curves of anti-malarial drugs against Plasmodium falciparum and Plasmodium vivax
| P. falciparum | P. vivax | ||||||
|---|---|---|---|---|---|---|---|
| Method | Geometric mean slope (95 % CI) | Median difference slopea (range) | Method | Geometric mean slope (95 % CI) | Median difference slopea (range) | ||
| Chloroquine (n = 31) | NONMEM | 3.09 (2.72–3.46) | Chloroquine (n = 29) | NONMEM | 3.86 (2.99–4.72) | ||
| GP | 3.15 (2.66–3.73) | 0.03 (−0.20 to 4.85) | GP | 3.48 (2.75–4.39) | 0.06 (−0.46 to 2.82) | ||
| ICE | 3.33 (2.84–3.91) | 0.17 (0.03 to 4.85) | ICE | 3.67 (2.93–4.60) | 0.20 (−0.46 to 2.82) | ||
| IVART | 3.40 (2.91–3.97) | 0.23 (−1.67 to 4.69) | IVART | 3.55 (2.85–4.42) | 0.21 (−2.20 to 4.90) | ||
| WNL | 3.08 (2.64–3.59) | 0.01 (−0.18 to 2.88) | WNL | 3.43 (2.71–4.35) | 0.03 (−0.46 to 2.82) | ||
| Piperaquine (n = 31) | NONMEM | 3.17 (2.58–3.76) | Piperaquine (n = 28) | NONMEM | 3.80 (3.17–4.43) | ||
| GP | 3.13 (2.54–3.85) | 0.08 (−0.50 to 3.63) | GP | 3.88 (3.03–4.96) | 0.02 (0.29 to 4.32) | ||
| ICE | 3.21 (2.59–3.96) | 0.21 (−0.07 to 3.63) | ICE | 4.13 (3.26–5.25) | 0.26 (0.03 to 4.32) | ||
| IVART | 3.07 (2.47–3.82) | 0.20 (−2.59 to 4.60) | IVART | 4.06 (3.24–5.09) | 0.26 (−0.92 to 4.32) | ||
| WNL | 2.83 (2.37–3.37) | 0.01 (−0.52 to 3.61) | WNL | 3.82 (3.01–4.86) | −0.01 (−0.26 to 4.16) | ||
| Mefloquine (n = 31) | NONMEM | 2.48 (2.18–2.78) | Mefloquine (n = 29) | NONMEM | 2.96 (2.53–3.38) | ||
| GP | 2.46 (2.10–2.89) | 0.03 (−0.15 to 5.04) | GP | 3.11 (2.48–3.91) | 0.01 (−0.23 to 5.07) | ||
| ICE | 2.60 (2.24–3.02) | 0.19 (0.01 to 5.04) | ICE | 3.25 (2.64–4.00) | 0.18 (0.04 to 5.19) | ||
| IVART | 2.38 (2.05–2.75) | 0.08 (−0.86 to 0.92) | IVART | 3.04 (2.53–3.65) | 0.19 (−1.63 to 5.19) | ||
| WNL | 2.42 (2.08–2.83) | 0.02 (−0.15 to 4.21) | WNL | 3.02 (2.41–3.78) | −0.01 (−0.69 to 5.05) | ||
| Amodiaquine (n = 30) | NONMEM | 4.43 (3.37–5.50) | Amodiaquine (n = 28) | NONMEM | 3.95 (3.26–4.65) | ||
| GP | 3.68 (2.89–4.70) | 0.06 (−0.37 to 4.67) | GP | 3.89 (3.03–4.98) | 0.06 (−0.54 to 4.50) | ||
| ICE | 4.01 (3.22–5.00) | 0.24 (0.03 to 4.67) | ICE | 4.12 (3.28–5.18) | 0.19 (−0.24 to 4.50) | ||
| IVART | 4.01 (3.22–5.00) | 0.24 (0.03 to 4.67) | IVART | 4.17 (3.33–5.24) | 0.19 (−0.24 to 4.50) | ||
| WNL | 3.64 (2.86–4.63) | 0.05 (−0.43 to 3.67) | WNL | 3.87 (3.03–4.95) | 0.02 (0.28 to 4.47) | ||
| Artesunate (n = 31) | NONMEM | 2.74 (2.38–3.10) | Artesunate (n = 28) | NONMEM | 2.74 (2.38–3.10) | ||
| GP | 2.63 (2.19–3.15) | −0.05 (−0.35 to 4.55) | GP | 3.67 (2.75–4.89) | 0.18 (−0.54 to 4.79) | ||
| ICE | 2.94 (2.49–3.46) | 0.20 (0.35 to 4.55) | ICE | 3.92 (3.01–5.10) | 0.24 (0.01 to 4.79) | ||
| IVART | 3.03 (2.52–3.65) | 0.32 (−0.68 to 7.12) | IVART | 3.84 (2.94–5.01) | 0.18 (−0.38 to 4.38) | ||
| WNL | 2.63 (2.19–3.15) | −0.01 (−0.37 to 4.51) | WNL | 3.64 (2.76–4.79) | 0.14 (−0.31 to 4.49) | ||
aMedian difference (range) for each method compared with NONMEM (values in italics) used as the reference method for comparison